Edgewise posts Q4 net loss $0.47/sh; pro-forma cash >$550M; multiple trial readouts in 2024

Edgewise Therapeutics, Inc.

2023-FY EPS reported -$1.57

Net loss for Q4 2023 was $30.1M ($0.47 per share), up from $25.7M ($0.41) in Q3 2023.
Cash, equivalents and marketable securities $318.4M at Dec 31, 2023; pro-forma >$550M after $231.8M net Jan 2024 offering.
R&D expenses $27.7M (+$3.9M QoQ); G&A $6.2M (+$0.5M QoQ) as clinical programs advanced.
Expect CANYON (Becker) data Q4 2024; ARCH 24-month, DUNE, and LYNX dose data in Q2 2024.
EDG-7500 Phase 1 data and Phase 2 obstructive HCM data expected Q3 2024; FOX trial dosing starts early 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Edgewise Therapeutics, Inc. reported financial results for fourth quarter and full year ended December 31, 2023.

Period: fourth quarter and full year ended December 31, 2023
Result: reported results

Exact text from the filing

On February 22, 2024, Edgewise Therapeutics, Inc. issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2023.

View on SEC.gov

Browse all earnings releases →

Edgewise Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-026336

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.